NASDAQ:ICCC - ImmuCell Stock Price, News & Analysis

+0.01 (+0.18 %)
(As of 09/19/2019 09:11 AM ET)
Today's Range
Now: $5.46
50-Day Range
MA: $5.73
52-Week Range
Now: $5.46
Volume496 shs
Average Volume5,284 shs
Market Capitalization$39.37 million
P/E RatioN/A
Dividend YieldN/A
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:ICCC



Sales & Book Value

Annual Sales$10.99 million
Book Value$3.96 per share


Net Income$-2,320,000.00


Market Cap$39.37 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) released its earnings results on Monday, August, 12th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. The biotechnology company earned $2.71 million during the quarter. ImmuCell had a negative net margin of 14.61% and a negative return on equity of 6.84%. View ImmuCell's Earnings History.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for ImmuCell.

Has ImmuCell been receiving favorable news coverage?

Media headlines about ICCC stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmuCell earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for ImmuCell.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest in August. As of August 15th, there was short interest totalling 2,000 shares, an increase of 33.3% from the July 15th total of 1,500 shares. Based on an average daily trading volume, of 6,800 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company's shares are short sold. View ImmuCell's Current Options Chain.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Who are ImmuCell's key executives?

ImmuCell's management team includes the folowing people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by many different of retail and institutional investors. Top institutional investors include Perritt Capital Management Inc. (1.80%), Ingalls & Snyder LLC (1.33%), Vanguard Group Inc. (1.30%), HM Payson & Co. (0.40%) and Eidelman Virant Capital (0.19%). View Institutional Ownership Trends for ImmuCell.

Which institutional investors are selling ImmuCell stock?

ICCC stock was sold by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc. and HM Payson & Co.. View Insider Buying and Selling for ImmuCell.

Which institutional investors are buying ImmuCell stock?

ICCC stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Eidelman Virant Capital and Ingalls & Snyder LLC. View Insider Buying and Selling for ImmuCell.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $5.46.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $39.37 million and generates $10.99 million in revenue each year. ImmuCell employs 47 workers across the globe.View Additional Information About ImmuCell.

What is ImmuCell's official website?

The official website for ImmuCell is

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel